Salix Pharma Meets FDA on Content, Format of Pending NDA for Rifaximin

Salix Pharmaceuticals Ltd. reported that it held a pre-NDA meeting with the FDA to discuss the company’s proposed new drug application for rifaximin in the treatment of patients with non-constipation irritable bowel syndrome.
RTTNews